Cordycepin (3'-deoxyadenosine) has no effect on the size or relative proportions of Newcastle disease virus-specific 18-22S mRNA species nor on the amount or size of the polyadenylic acid associated with them. Cordycepin does, however, cause an inhibition of incorporation of [3H] 
A. Bratt, manuscript in preparation; SpanierCollins et al., in preparation). In NDV-infected chicken embryo cells, there are also partially base-paired virus-specific RNA species sedimenting from 35 to 50S which are intermediates in the synthesis of virion RNA and mRNA (B. Spanier-Collins and M. A. Bratt, manuscript in preparation). It would be useful to be able to preferentially inhibit viral genome replication, transcription of mRNA, or the synthesis of the poly(A) associated with this mRNA. This might allow us to independently study the mechanism and molecules and intermediates involved in one of the processes and, if poly(A) synthesis were preferentially inhibited, to learn something about the function of viral poly(A).
Cordycepin (3'-deoxyadenosine) appears to have differential effects on the synthesis of various RNA species in eukaryotic cells. It has little effect on the synthesis of heterogeneous nuclear RNA but inhibits poly(A) synthesis and the appearance of mRNA on polysomes (1, 9, 13, 17, 18) . It also seems to cause a reduction in size of ribosomal precursor RNAs and to inhibit mitochondrial RNA synthesis (18) . We therefore tested this drug for differential effects on NDV-specific RNA species synthesized in infected chicken embryo cells. We report here that cordycepin preferentially inhibits incorporation of [3H]uridine into 50S virus-specific RNA relative to 18-22S without affecting the size or relative proportions of the 18-22S mRNA's or the amount or size of their associated poly(A) Virus purification and infectivity assays. NDV-HP (Israel HP, 1935) (3) was grown in embryonated hens' eggs and then concentrated from the allantoic fluid by centrifugation in a Spinco SW27 rotor for 1 h at 4 C and 24,000 rpm (74,800 x g) in standard buffer through 20% sucrose onto a 65% sucrose-D20 pad. Virus at the interface of the two sucrose layers was then diluted in Tris-saline containing 2% calf serum and stored at -70 C. Infectivity titrations by plaque formation (PFU per milliliter) were carried out as described previously (5) but using standard medium (see above).
Virus growth curve. Growth curves were done as previously described (11) except adsorption was for 45 min and incubation was at 40 C. The end of the virus adsorption period is defined as zero time.
Cell culture procedures. Secondary cultures of chicken embryo cells were prepared and grown in a 5% CO2 atmosphere as previously described (3) Intracellular RNA. Virus-specific RNA was labeled in the following manner. Cultures were infected at an input multiplicity of 5 PFU/cell with NDV-HP and incubated at 40 C. ActD at 10 ,ug/ml was always added 45 min before labeling. Cordycepin or cycloheximide was added at the concentrations and times indicated. Labeling was with 50 to 100 ,uCi of [3H]uridine or [3H]adenosine per ml for the periods indicated in each experiment. After labeling, the cells were solubilized in solubilizing buffer, phenol extracted three times with buffersaturated phenol, and precipitated twice in ethanol as previously described (4) .
Host cell RNA to be used as marker was labeled during a 24-h incubation with 500 ,uCi of 32p per ml and then purified as described for virus-specific RNA.
Fractionation and analysis of RNA. Velocity sedimentation analysis were performed as follows. RNA dissolved in SDS-standard buffer was layered on 12-ml linear 15 to 30% sucrose gradients containing the same buffer. Centrifugation was carried out at 22 C and 39,000 rpm (180,000 x g) in a Spinco SW41 rotor for 4 h. Fractions (0.4 ml) were collected from the top using an ISCO (Instrumentation Specialties Co.) fractionator, which measured adsorbance at 260 nm, coupled to an ISCO fraction collector. Samples of each fraction were counted directly in aquasol or trichloroacetic acid precipitated and counted using previously described procedures (6) .
RNase digestion was done by incubating RNA at 37 C for 1 h in 2x SSC, 50 itg of pancreatic RNase per ml, and 25 U of Ti RNase per ml.
Oligo(dT)-cellulose binding was done in the following way. RNA, in 1 ml of column-binding buffer, was added to a column of 0.1 g of oligo(dT)-cellulose (previously washed with binding buffer) in a Pasteur pipette. The column was washed with three 1-ml aliquots of binding buffer and then four 1-ml aliquots of column elution buffer. These 1-ml fractions were trichloroacetic acid precipitated. Most of the radioactivity is in the first 2 ml of binding buffer and the first 2 ml of elution buffer. Therefore, the RNA in these fractions is designated as binding and nonbinding RNA, respectively.
Acrylamide gel electrophoresis was carried out using 10-cm 4 or 10% ethylene diacrylate crosslinked polyacrylamide gels according to the procedures, including gel slicing and counting, of Collins and Bratt (8) .
Amino acid labeling. Cells were infected as in RNA labeling experiments. Drugs were added after adsorption of the virus. Labeling was for 30 min with 10 ,1Ci of [3H]amino acids per ml at the times indicated. After labeling, cells were washed with Trissaline and removed from the plates with 1 N NaOH. Samples of this were trichloroacetic acid precipitated after boiling for 5 min.
RESULTS
Inhibition of virus multiplication. Figure 1 shows that 50 ,ug of cordycepin per ml, in the presence or absence of 10 Ag of ActD per ml, inhibits the appearance of infectious virus almost completely (>95%) if added soon after infection. Cordycepin is significantly less effective when added 4 h after infection.
Effects on intracellular virus-specific 18-22S RNA and poly(A). Figure 2 shows the sucrose velocity sedimentation patterns ofintracellular virus-specific RNA labeled with [3H]uridine ( Fig. 2A) or [3H]adenosine (Fig. 2B ) in the presence of 10 ,ug of ActD per ml and in the presence or absence of 50 ,ug of cordycepin per ml. The usual 18-22S, 358, and 50S NDV RNA species (4) are present in the cultures that did not receive cordycepin. In drug-treated cultures, the major effect of cordycepin is an apparent decrease in the ratio of 50 to 18-22S RNA. To more precisely analyze any possible effects of cordycepin on the 18-22S RNA, [3H]uridine-labeled 18-22S RNA, synthesized in the absence (Fig. 3A) or presence ( Fig. 3B ) of cordycepin, was analyzed by gel electrophoresis. The patterns are similar to those obtained previously (8, 21) , and there are no major differences in the migration rates or relative proportions of these RNA species when synthesized in the presence or absence of cordycepin.
The following experiments suggest that there is little, if any, effect of cordycepin on the synthesis of the poly(A) associated with NDV 18 size, with an average size of 4-5S. Thus, cordycepin has no effect on the size of the poly(A) associated with NDV mRNA.
Effects of protein synthesis inhibition on the ratio of 50S to 18-22S RNA. The results described thus far suggest that cordycepin has little or no effect on NDV mRNA. However, the reduction in incorporation of [3H]uridine and [3Hladenosine into 5(S intracellular RNA relative to 18-22S (Fig. 2) inhibition is dependent on drug concentration and the time period of treatment with the drug before labeling (data not shown). This effect of cordycepin on the ratio of 50S to 18-22S RNA is similar to that produced by treating paramyxovirus-infected cultures with the protein synthesis inhibitor cycloheximide (6, 20) . Cordycepin has also been reported to inhibit protein synthesis (7). Therefore, it seemed possible that the reduction of 50S RNA accumulation relative to 18-22S might be a secondary effect of the inhibition of protein synthesis and not a direct effect on 50S RNA synthesis.
To quantitatively compare the effects of cordycepin with a known inhibitor of protein synthesis, we first determined the extent to which cordycepin inhibits a Fractions were pooled from gradients similar to those in Fig. 2 , and duplicate samples were treated with RNase as described in Materials and Methods. Three separate preparations of RNA were used (experiments 1, 2, 3). Percentage of resistance is defined as the ratio of trichloroacetic acid-precipitable counts before and after treatment, times 100.
bFractions were pooled as in a, and the amount of counts binding to oligo(dT)-cellulose columns was determined as described in Materials and Methods. Percentage of binding is defined as the ratio of columnbinding counts to total counts added to the column, times 100. cetic acid-precipitable material at various times after the addition of cordycepin to uninfected and infected chicken embryo cells. This rate of accumulation in the presence of cordycepin (relative to the untreated control) decays with a half-life of about 2 to 2.5 h (Fig. 5) kinetics of inhibition are independent of the time during infection that the drug is added (data not shown). A small inibition oftrichloroacetic acid-soluble radioactivity is also observed in the presence of cordycepin (data not shown), but this is not enough to account for the inhibition of trichloroacetic acid-precipitable radioactivity seen here. We also determined the effect of ActD on amino acid accumulation, because it was used in all the RNA labeling experiments. ActD (10 ,ug/ml) inhibits amino acid incorporation but with slower kinetics than cordycepin (Fig. 5) , and ActD and cordycepin together show an effect similar to cordycepin alone. 
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Next we determined the concentration of cycloheximide that inhibits amino acid incorporation to the same extent as 50 Ag of cordycepin per ml. We found that 0.1 ,ug of cycloheximide per ml (in the presence of 10 ,ug of ActD per ml) inhibits amino acid incorporation by about 50% in NDV-infected chicken embryo cells (data not shown) and, after a 2.5-h incubation, 50 Ag of cordycepin per ml (in the presence or absence of ActD) causes a similar inhibition. (The amount of inhibition after 2.5 h of cordycepin treatment varies from 50% in many experiments to as much as 65%, as seen in Fig. 5.) Finally, we compared the patterns of [3H]uridine-labeled virus-specific RNA extracted from cells that were treated with cordycepin or cycloheximide with RNA patterns from untreated control cells (Fig. 6) . All of the RNA was labeled in the presence of ActD. When cordycepin or cycloheximide was used, it was added to the cells 2.5 h before labeling and was present during labeling. Figure 6A shows the control pattern of RNA. The usual 18-22S, 35S, and 50S species are present (The relative amounts of virus-specific 50S and 18-22S RNA synthesized in the presence of ActD by NDV-HP varies greatly from one experiment to the next [compare the patterns in Fig. 2A and Fig.  6A ] but are always constant within one experiment.) Figure 6B shows the pattern of RNA a Total counts in the 50S and 18-22S regions of the gradients in Fig. 6 were calculated, and the total 50S counts were divided by the total 18-22S counts.
b The values in the first column were divided by the ratio for the control and multiplied by 100.
extracted from cells that were treated with 50 ,zg of cordycepin per ml, and Fig. 6D shows the pattern of RNA from cells that were treated with 0.1 ,ug of cycloheximide per ml. In both the cordycepin-and cycloheximide-treated cells, the amount of label in 50S RNA relative to 18-22S is reduced. The ratios of 50S to 18-22S are about 51% of the control in RNA labeled in the presence of 50 ,ug of cordycepin per ml and 64% of the control in RNA labeled in the presence of 0.1 ,ug of cycloheximide per ml (Table 2 ). Therefore, when amino acid incorporation is inhibited by about 50% by cycloheximide or cordycepin, there is approximately the same effect on the ratio of 50S to 18-22S RNA. Figure 6C shows the pattern of RNA from cells that were treated with a much higher concentration of cycloheximide, 50 (Table 2) . DISCUSSION Cordycepin has no effect on the size or relative proportions of the six to seven 18-22S NDV mRNA species; nor does it have an effect on the poly(A) associated with this RNA. This is in contrast to the poly(A) associated with the heterogeneous nuclear and mRNA of eukaryotic cells, the synthesis of which is inhibited by cordycepin (1, 9, 13, 17) . NDV RNA is synthesized solely in the cytoplasm (4). NDV virions and cores isolated from virions by detergent treatment can synthesize 18-22S RNA (6, 12) and its associated poly(A) (21) in vitro. There is also evidence suggesting that NDV poly(A) is not transcribed from polyuridylic acid sequences in virion RNA (16) . This suggests that NDV has its own poly(A)-synthesizing activity, but it is still possible that the enzyme that synthesizes viral poly(A) is a cellular, cytoplasmic, cordycepin-insensitive enzyme that is incorporated into virus particles.
It has been shown that the protein synthesis inhibitor cycloheximide alters the ratio of 50S to 18-22S RNA in paramyxovirus-infected cells (6, 20) , probably because it inhibits the replication of virion RNA (Spanier-Collins and Bratt, in preparation). We have shown here that cordycepin, another inhibitor of protein synthesis, also alters this ratio. At concentrations ofcordycepin and cycloheximide that inhibit amino acid incorporation to the same extent, there is a similar effect on the ratio of 50 to 18-22S RNA. The inhibition of amino acid incorporation by cordycepin increases with time of drug treatment (Fig. 5) ; the effect of cycloheximide is faster. By 1 h after addition of the drug, the maximum effect is seen (data not shown). It is noteworthy that cycloheximide and cordycepin, which show different kinetics of inhibition of amino acid accumulation and almost certainly work through different mechanisms, have similar effects on nucleotide incorporation into NDV intracellular 50S RNA relative to 18-22S RNA. Although we have not ruled out all other possibilities, it seems probable that the effect of cordycepin on 5S RNA is a secondary effect of protein synthesis inhibition.
Whereas cycloheximide and cordycepin always inhibit the incorporation of [3H]uridine into 5S RNA relative to 18-22S RNA, they have different effects on the absolute number of counts incorporated into 18-22S RNA. Cycloheximide consistently causes an increase in the amount of incorporation into 18-22S RNA. The effect is most dramatic at the high cycloheximide concentration (see Fig. 6 ). Cordycepin, on the other hand, causes a decrease in the absolute amount of label incorporated into 18-22S RNA, but only when RNA is labeled under certain conditions. In experiments like the one shown in Fig. 2 , where labeling is for 5 h after a 45-min drug pretreatment, approximately the same amount of label is incorporated into 18-22S RNA with or without cordycepin. When cells are labeled for 90 min after a 2.5-h pretreatment, as in Fig. 6 , less 18-22S RNA is labeled in the presence of cordycepin than in the control. These differences in the absolute amounts of label incorporated do not necessarily indicate changes in rates of RNA synthesis. For example, adenosine has been reported to compete with uridine for transport into the cell and thereby alter the amount of [3H]uridine taken up by cells (19) . Cordycepin, an adenosine analogue, may also show these effects. The inhibition of total incorporation may be a reflection of less [3H]uridine being available for RNA synthesis in cordycepintreated cells after a long pretreatment with drugs.
It has previously been shown that the growth of NDV and Sendai virus (15) is inhibited by cordycepin, whereas the growth of vesicular stomatitis virus (10) and influenza virus (15) is not. We have confirmed that the growth of NDV is drastically inhibited by cordycepin. Our results argue against the interpretation that the different sensitivities of these viruses to cordycepin are due to different sensitivities of the viral transcriptase or poly(A)-synthesizing activities to the drug. The growth inhibition, at least in the case of NDV, does not result from an inhibition of poly(A) synthesis as has been suggested by Mahy et al. (15) . However, it is probably at least partially due to an inhibition of 50S viral RNA accumulation, which is probably a secondary effect of the inhibition of protein synthesis.
